New immune therapy trial targets Early-Stage blood cancer
NCT ID NCT07128641
Summary
This study is testing an immunotherapy drug called odronextamab in people with a specific type of slow-growing blood cancer (follicular lymphoma) who have not yet received any treatment and have a low amount of cancer. The goal is to see if this drug, which helps the body's own immune system fight cancer cells, is safe and effective at putting the cancer into remission. About 35 participants will receive the drug for about 4 months and then be followed for up to 15 years to track their long-term health.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.